EPI-743 in Friedreich's Ataxia Point Mutations

EPI-743 in Friedreich's Ataxia Point Mutations.

The purpose of this study is to evaluate the effects of EPI-743 in patients with Friedreich's Ataxia point mutations.

Official Title: A Phase 2A Clinical Trial of EPI-743 (Vincerinone™) on Visual Function in Friedreich's Ataxia Patients With Point Mutations.

Sponsor: University of South Florida
Collaborators: Edison Pharmaceuticals Inc, Friedreich's Ataxia Research Alliance

Sequence Complexity Effects on Speech Production in Healthy Speakers and Speakers with Hypokinetic or Ataxic Dysarthria

Sequence Complexity Effects on Speech Production in Healthy Speakers and Speakers with Hypokinetic or Ataxic Dysarthria.Reilly KJ, Spencer KA, PLoS ONE 8(10): e77450. doi:10.1371/journal.pone.0077450. (2013)

FULL TEXT PDF

Friedreich’s ataxia and other hereditary ataxias in Greece: An 18-year perspective

Friedreich’s ataxia and other hereditary ataxias in Greece: An 18-year perspective. Georgios Koutsis, Athina Kladi, Georgia Karadima, Henry Houlden, Nicholas W. Wood, Kyproula Christodoulou, Marios Panas; Journal of the Neurological Sciences, Available online 16 October 2013; http://dx.doi.org/10.1016/j.jns.2013.10.012

Keywords: Friedreich’s ataxia; spinocerebellar ataxia; autosomal recessive cerebellar ataxia; autosomal dominant cerebellar ataxia; SCA